Literatur
-
1
Adam B, Liebregts T, Best J, Bechmann L, Lackner C, Neumann J, Koehler S, Holtmann G.
A combination of peppermint oil and caraway oil attenuates the post-inflammatory visceral hyperalgesia in a rat model.
Scand J Gastroenterol.
2006;
41
155-160
-
2
Adam B, Liebregts T, Gschossmann J M, Krippner C, Scholl F, Ruwe M, Holtmann G.
Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model.
Pain.
2006;
123
179-186
-
3
Agreus L, Svardsudd K, Nyren O, Tibblin G.
Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time.
Gastroenterology.
1995;
109
671-680
-
4
Arents N L, Thijs J C, van Zwet A A. et al .
Approach to treatment of dyspepsia in primary care: a randomized trial comparing „test-and-treat” with prompt endoscopy.
Arch Intern Med.
2003;
163
1606-1612
-
5
Berger M Y, van der Velden J J, Lijmer J G, de Kort H, Prins A, Bohnen A M.
Abdominal symptoms: do they predict gallstones? A systematic review.
Scand J Gastroenterol.
2000;
35
70-76
-
6
Bundy R, Walker A F, Middleton R W, Marakis G, Booth J C.
Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis.
J Altern Complement Med.
2004;
10
667-669
-
7
Camilleri M, Chey W Y, Mayer E A. et al .
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Arch Intern Med.
2001;
161
1733-1740
-
8
Camilleri M, Northcutt A R, Kong S, Dukes G E, McSorley D, Mangel A W.
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Lancet.
2000;
355
1035-1040
-
9
Camilleri M.
Review article: tegaserod.
Aliment Pharmacol Ther.
2001;
15
277-289
-
10
Coffin B, Farmachidi J P, Rueegg P, Bastie A, Bouhassira D.
Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects.
Aliment Pharmacol Ther.
2003;
17
577-585
-
11
Corsetti M, Caenepeel P, Fischler B, Janssens J, Tack J.
Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia.
Am J Gastroenterol.
2004;
99
1152-1159
-
12
Delaney B C, Wilson S, Roalfe A. et al .
Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care.
Lancet.
2000;
356
1965-1969
-
13
Drossman D A, Leserman J, Nachman G. et al .
Sexual and physical abuse in women with functional or organic gastrointestinal disorders.
Ann Intern Med.
1990;
113
828-833
-
14
Drossman D A, Toner B B, Whitehead W E. et al .
Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.
Gastroenterology.
2003;
125
19-31
-
15
Drossman D A.
Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome?.
Am J Med.
1999;
107
41S-50S
-
16
Ford A C, Qume M, Moayyedi P. et al .
Helicobacter pylori „test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis.
Gastroenterology.
2005;
128
1838-1844
-
17
Gwee K A.
Irritable bowel syndrome in developing countries-a disorder of civilization or colonization?.
Neurogastroenterol Motil.
2005;
17
317-324
-
18
Hammer J, Eslick G D, Howell S C, Altiparmak E, Talley N J.
Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia.
Gut.
2004;
53
666-672
-
19
Holtmann G, Gschossmann J, Buenger L, Gerken G, Talley N J.
Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?.
Gastroenterology.
2002;
123
1451-1458
-
20
Holtmann G, Gschossmann J, Karaus M. et al .
Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia.
Aliment Pharmacol Ther.
1999;
13
1459-1465
-
21
Holtmann G, Talley N J, Liebregts T, Adam B, Parow C.
A placebo-controlled trial of itopride in functional dyspepsia.
N Engl J Med.
2006;
354
832-840
-
22
Lembo A J, Olden K W, Ameen V Z, Gordon S L, Heath A T, Carter E G.
Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Clin Gastroenterol Hepatol.
2004;
2
675-682
-
23
Liebregts T, Adam B, Bertel A, Lackner C, Neumann J, Talley N J, Gerken G, Holtmann G.
Psychological stress and the severity of post-inflammatory visceral hyperalgesia.
Eur J Pain.
2006;
-
24
Liu J H, Chen G H, Yeh H Z, Huang C K, Poon S K.
Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial.
J Gastroenterol.
1997;
32
765-768
-
25
Locke G R, Zinsmeister A R, Fett S L, Melton L J, Talley N J.
Overlap of gastrointestinal symptom complexes in a US community.
Neurogastroenterol Motil.
2005;
17
29-34
-
26
Longstreth G F, Drossman D A.
Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs.
Clin Gastroenterol Hepatol.
2005;
3
397-400
-
27
Longstreth G F, Thompson W G, Chey W D, Houghton L A, Mearin F, Spiller R C.
Functional bowel disorders.
Gastroenterology.
2006;
130
1480-1491
-
28
Longstreth G F, Yao J F.
Irritable bowel syndrome and surgery: a multivariable analysis.
Gastroenterology.
2004;
126
1665-1673
-
29
Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J.
Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial.
Digestion.
2004;
69
45-52
-
30
Madisch A, Holtmann G, Plein K, Hotz J.
Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.
Aliment Pharmacol Ther.
2004;
19
271-279
-
31
Moayyedi P, Feltbower R, Brown J. et al. Leeds HELP Study Group .
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial.
Lancet.
2000;
355
1665-1669
-
32
Moayyedi P, Soo S, Deeks J. et al .
Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Cochrane Database Syst Rev.
2005;
CD002096
-
33
O’Donnell L J, Virjee J, Heaton K W.
Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.
Bmj.
1990;
300
439-440
-
34
O’Mahony L, McCarthy J, Kelly P. et al .
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
Gastroenterology.
2005;
128
541-551
-
35
Owens D M, Nelson D K, Talley N J.
The irritable bowel syndrome: long-term prognosis and the physician-patient interaction.
Ann Intern Med.
1995;
122
107-112
-
36
Saito Y A, Schoenfeld P, Locke G R.
The epidemiology of irritable bowel syndrome in North America: a systematic review.
Am J Gastroenterol.
2002;
97
1910-1905
-
37
Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J.
Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia.
Am J Gastroenterol.
2003;
98
783-788
-
38
Straus W L, Ofman J J, MacLean C. et al .
Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions.
Am J Gastroenterol.
2002;
97
1951-1958
-
39
Tack J, Talley N J, Camilleri M, Holtmann G, Hu P, Malagelada J R, Stanghellini V.
Functional gastroduodenal disorders.
Gastroenterology.
2006;
130
1466-1479
-
40
Talley N J, Vakil N.
Guidelines for the management of dyspepsia.
Am J Gastroenterol.
2005;
100
2324-2337
-
41
Talley N J, Verlinden M, Jones M.
Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia?.
Am J Gastroenterol.
2001;
96
1422-1428
-
42
Talley N J, Zinsmeister A R, Schleck C D, Melton L J.
Dyspepsia and dyspepsia subgroups: a population-based study.
Gastroenterology.
1992;
102
1259-1268
-
43
Thomson A B, Barkun A N, Armstrong D. et al .
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study.
Aliment Pharmacol Ther.
2003;
17
1481-1491
-
44
Walker A F, Middleton R W, Petrowicz O.
Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study.
Phytother Res.
2001;
15
58-61
-
45
Gonsalkorale W M, Toner B B, Whorwell P J.
Cognitive Change in patients undergoing hypnotherapy for irritable bowel syndrome.
J Psychosom Res.
2004;
56
271-278
-
46
Kuepper-Nybelen J, Thefeld W, Rothenbacher D.
Patterns of alcohol consumption and Helicobacter pylory infection: results of a population based study from Germany among 6545 adults.
Aliment Pharmacol Ther.
2005;
21
57-64
-
47
Roberts L, Wilson S, Singh S. et al .
Gut-directed hypnotherapy for irritable bowel-syndrome: piloting a primary care-based randomised controlled trial.
Br J Gen Pract.
2006;
56
115-121
-
48
van Kerkhoven L A, van Rossum L G, van Oijen M G. et al .
Upper gastrointestinal endoscopy does not reassure patients with functional dyspepsia.
Endoscopy.
2006;
38
879-885
Prof. Dr. med. Gerald Holtmann
Royal Adelaide Hospital, University of Adelaide, Department of Gastroenterology, Hepatology and General Medicine
North Tce
Adelaide, SA 5000
Australia
Phone: +61/8/82222412
Fax: +61/8/82222414
Email: gerald.holtmann@adelaide.edu.au
